Annual Cash & Cash Equivalents
$9.29 M
-$4.23 M-31.27%
December 31, 2023
Summary
- As of February 8, 2025, CMMB annual cash & cash equivalents is $9.29 million, with the most recent change of -$4.23 million (-31.27%) on December 31, 2023.
- During the last 3 years, CMMB annual cash & cash equivalents has fallen by -$2.38 million (-20.40%).
- CMMB annual cash & cash equivalents is now -38.81% below its all-time high of $15.19 million, reached on December 31, 2021.
Performance
CMMB Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$6.60 M
+$1.56 M+31.08%
September 1, 2024
Summary
- As of February 8, 2025, CMMB quarterly cash and cash equivalents is $6.60 million, with the most recent change of +$1.56 million (+31.08%) on September 1, 2024.
- Over the past year, CMMB quarterly cash and cash equivalents has increased by +$1.56 million (+31.08%).
- CMMB quarterly cash and cash equivalents is now -88.65% below its all-time high of $58.18 million, reached on March 31, 2021.
Performance
CMMB Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CMMB Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -31.3% | +31.1% |
| 3 y3 years | -20.4% | +31.1% |
| 5 y5 years | -20.4% | +31.1% |
CMMB Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -38.8% | at low | -68.2% | +41.5% |
| 5 y | 5-year | -38.8% | at low | -88.7% | +41.5% |
| alltime | all time | -38.8% | at low | -88.7% | +41.5% |
Chemomab Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $6.60 M(+31.1%) |
| Jun 2024 | - | $5.04 M(+8.0%) |
| Mar 2024 | - | $4.67 M(-49.8%) |
| Dec 2023 | $9.29 M(-31.3%) | $9.29 M(-10.5%) |
| Jun 2023 | - | $10.38 M(-50.0%) |
| Mar 2023 | - | $20.77 M(+53.6%) |
| Dec 2022 | $13.52 M | $13.52 M(+25.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $10.74 M(+8.7%) |
| Jun 2022 | - | $9.88 M(-28.5%) |
| Mar 2022 | - | $13.83 M(-8.9%) |
| Dec 2021 | $15.19 M(+30.1%) | $15.19 M(-59.8%) |
| Sep 2021 | - | $37.74 M(-16.9%) |
| Jun 2021 | - | $45.40 M(-22.0%) |
| Mar 2021 | - | $58.18 M(+398.4%) |
| Dec 2020 | $11.67 M | $11.67 M |
FAQ
- What is Chemomab Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Chemomab Therapeutics?
- What is Chemomab Therapeutics annual cash & cash equivalents year-on-year change?
- What is Chemomab Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Chemomab Therapeutics?
- What is Chemomab Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Chemomab Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of CMMB is $9.29 M
What is the all time high annual cash & cash equivalents for Chemomab Therapeutics?
Chemomab Therapeutics all-time high annual cash & cash equivalents is $15.19 M
What is Chemomab Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, CMMB annual cash & cash equivalents has changed by -$4.23 M (-31.27%)
What is Chemomab Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CMMB is $6.60 M
What is the all time high quarterly cash and cash equivalents for Chemomab Therapeutics?
Chemomab Therapeutics all-time high quarterly cash and cash equivalents is $58.18 M
What is Chemomab Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, CMMB quarterly cash and cash equivalents has changed by +$1.56 M (+31.08%)